Sign in
KLTOW Stock Price, Chart, Stats & News
Klotho Neurosciences, Inc.
Save
6.26M
Market cap
–
Current P/E
–
Forward P/E
KLTOW chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -112.08% |
ROE | -201.59% |
D/E | – |
Interest coverage ratio | -1.90x |
KLTOW valuation
P/E | – |
P/S | – |
P/B | 3.14x |
P/CF | -5.61x |
P/FCF | -4.97x |
P/OCF | -5.61x |
PEG | -0.10x |
EV multiple | -4.66x |
About
Klotho Neurosciences, Inc. is a biopharmaceutical company focused on developing medical treatments for a variety of severe illnesses, including cancer, heart disease, and conditions affecting the nervous system. Among its key product initiatives are gene therapy candidates: AMI-101, designed for either preventing or treating Alzheimer's disease, and AMI-202, intended to manage and prevent amyotrophic lateral sclerosis (ALS). The company, situated in Omaha, Nebraska, changed its corporate identity to Klotho Neurosciences, Inc. in September 2024, having previously been known as Anew Medical, Inc.
Similar securities
Based on sector and market capitalization
Report issue